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Abstract
This prospective trial investigated the population pharmacokinetics of piperaquine, given with 
dihydroartemisinin to treat uncomplicated malaria in 107 Ugandan children 6 months to 2 years 
old, an age group previously unstudied. Current weight-based dosing does not adequately address 
physiological changes in early childhood. Patients were administered standard three-day oral doses 
and provided 1,282 capillary plasma concentrations from 218 malaria episodes. Less than 30% of 
treatments achieved 57 ng/mL on day 7. A three-compartment model with first-order absorption 
described the data well. Age had a statistically significant effect (p<0.005) on clearance/
bioavailability in a model that accounts for allometric scaling. Simulations demonstrated that 
higher doses in all children, but especially in those with lower weight for age, are required for 
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adequate piperaquine exposure, though safety and tolerance will need to be established. These 
findings support other evidence that both weight and age-specific guidelines for piperaquine 
dosing in children are urgently needed.
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Introduction
Malaria remains among the most significant causes of morbidity and mortality in the 
developing world. Those most at risk are children less than five years of age and pregnant 
women, predominantly in sub-Saharan Africa. Currently, the World Health Organization 
(WHO) recommends artemisinin-based combination therapies (ACTs) as first-line treatment 
for uncomplicated Plasmodium falciparum malaria in all risk groups, except during the 1st 
trimester of pregnancy. (1) Dihydroartemisinin-piperaquine (DP) is among the most effective 
ACT regimens, all of which combine a short-acting artemisinin derivative with a long-acting 
partner drug, in this case, piperaquine (PQ).
While artemisinin is more potent for reducing parasite burden, PQ protects against 
recrudescent malaria, emergence of parasites with reduced artemisinin sensitivity, and 
extends the period of post-treatment protection against recurrent infection due to its 
prolonged duration in the body. (2) PQ has amongst the longest terminal half-lives of 
currently used partner drugs, approximately 23 days in children 2–10 years of age. (3) In a 
mixed population of adults and children 3 years of age and older, all of whom had malaria, 
the mean terminal half-life of PQ was reported to be 28 days (4) and in healthy subjects 
given a single 500 mg to 1500 mg dose, it ranged from 11–18 days. (5)
Few pharmacokinetic (PK) studies have been published for ACT regimens in young children 
from sub-Saharan Africa (3) or elsewhere, (6, 7, 8) and none specifically study DP in 
children under 2 years of age. Currently recommended doses of DP to treat malaria in young 
children were chosen by scaling adult doses based on weight, with the implied target of a 
similar plasma concentration-time profile. (1, 9) Such an approach does not adequately 
address physiological changes inherent to early childhood that affect PK, such as maturation 
of hepatic and gastrointestinal isoenzymes and altered distribution. (10) Even with 
developmental considerations, PK predictions in children are imperfect and require re-
evaluation once clinical data become available. In anticipation that millions of doses of DP 
are likely to be administered yearly as treatment or for prevention, (11, 12) it is critical to 
understand the PK of PQ so that its use can be optimized, particularly in those most at risk 
of disease. Using a population PK approach (13) coupled with small volume capillary 
plasma sampling for drug levels, (14, 15) we undertook a prospective population PK study 
of PQ in children aged 6 months to 2 years in the high transmission area of Tororo, Uganda.
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Participants in this PK were part of a larger malaria treatment trial in Uganda. (16) Blood 
samples for PK analysis were collected in 107 patients during each of 218 episodes of 
malaria treatment. Covariates were measured on the first treatment day of each occasion, 
with the exception of vomiting which was assessed during the first three days. Continuous 
covariate values, reported as the median of the individuals’ means across treatments (and 
range) are as follows: age 445 (206 to 693) days; body weight 9.0 (5.1 to 12.5) kg; 
hemoglobin 10.0 (5.6 to 14.7) g/dL; baseline parasite density 45,126 (32 to 322,560) 
parasites/mL; and height-for-age z-score −2.2 (−5.8 to 0.6). The occurrence of each 
categorical covariate that was assessed is as follows: female (n=43); breast fed during at 
least one occasion (n=50); vomiting in association with drug administration during at least 
one occasion (n=25); trimethoprim-sulfamethoxasole (TS) use during at least one occasion 
(n=41); HIV infected status (n=12); and antiretroviral therapy (ART) use (n=10).
In total, there were 1,282 evaluable capillary plasma concentrations at the following nominal 
times: day 0 (baseline) (n=118); pre- and post-last dose, which occurred on day 2 (n=212); 
day 3 (24-hour post-last dose) (n=213); day 7 (n=208); day 14 (n=217); day 21 (n=196); and 
day 28 (26 days post-last dose) (n=118). Figure 1 shows the individual plasma 
concentration-time curves of PQ for all children in the study. The number of concentration-
time points from each occasion is as follows: 1st=571; 2nd=471; 3rd=214 and 4th=26. Three 
additional samples were excluded from the analysis because they were below the limit of 
quantification.
The PQ plasma-concentration time data were well described with a three-compartment open 
model with first-order absorption. This model resulted in a better fit than a two-compartment 
model, both with and without the inclusion of covariates (p<0.0001 in each instance). The 
addition of an absorption lag time, with a point estimate of 0.32 h, was marginally 
statistically significant (p=0.0074, with ‘significance’ level predefined as p=0.005), but 
resulted in instability of the convergence of parameter estimation and was not retained in the 
model. Given the finding of “multiple peaks” seen in some individuals, we attempted to 
incorporate enterohepatic recirculation into the model. There was no evidence that 
enterohepatic recirculation accounted for these peaks (results not shown), though the 
sensitivity of our analysis was limited by the fact that this was a multi-dose study of an 
orally administered drug.
The covariate body weight was included unconditionally in the model for each of the three 
clearance parameters by multiplying each parameter by (weight/reference weight)0.75, and in 
each of the three volume of distribution parameters by multiplying each parameter by 
(weight/reference weight). The reference weight was approximately that of a one year old in 
this study population, 8.36 kg. Upon singular deletion of each allometric term, the objective 
function value (OFV) either decreased (though not statistically significantly), or increased, 
indicating their inclusion did not worsen the goodness of fit (GOF).
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An age effect on clearance/bioavailability (CL/F), was the only statistically significant 
covariate effect identified (p<0.002). The effect of age on F only (i.e., in the absence of age 
effect on CL/F) was marginally significant (p=0.0076). The goodness of fit with the 
combination of age effect on both CL/F and F was not significantly improved compared to 
that with its incorporation in either CL/F alone (p=0.20) or F alone (p=0.034). Alternative 
forms of the model of age effect on CL/F that were tested included a linear model [e.g., 
θx•(1−AGE/reference AGE • θy)] and a model with first-order change as a function of time 
[e.g., θx•(1−e−θy•AGE)], but they did not have a lower OFV relative to a nonlinear model 
(below). No other covariates were identified as having a significant influence on any 
clearance or volume of distribution parameter.
The final model for the typical value (indicated by the tilde) of CL/F is as follows:
(Equation 1)
in which AGEi is the age (month), and WTi the body weight (kg), of the ith child. Age was 
centered at 12 months, and weight at 8.36 kg (the approximately median value of a 1 year 
old in this population), for ease of interpretation. Figure 2 shows the relationship of CL/F 
with both body weight and age. The terminal t1/2, calculated from the primary parameters, 
was 31 days. Based on Equation 1, the predicted CL/F for the typical child 6 months of age 
is 4.4 L/h, for 1 year it is 6.4 L/h, and for 2 years 9.8 L/h. The corresponding weight-
adjusted CL/F for a typical 1 year old is 0.76 L/h/kg. The estimates of all parameters in the 
final model are provided in Table 1.
A full covariance matrix for inter-individual variability (IIV) was modelled, using an 
exponential form of the model for each PK parameter. The estimates of the diagonal 
elements only are reported in Table 1. Inter-occasion (among treatments within a patient) 
variability (IOV) of F and CL were both statistically significant (p<0.0001) and each 
estimated to be approximately 22%. Covariate hypothesis testing was performed with both 
IIV and IOV included in the model. The residual error, modelled as exponential 
(implemented by addition of a single additive error term to the log-transformed data), was 
estimated to be 61% (95% CI 59, 63%).
Figure 3 shows the goodness of fit (GOF) of the final model (with age effect on CL/F). A 
visual predictive check (Figure 4), shows good performance of the final model, with the 
median predictions falling in the middle of the data, and approximately 10% of the data 
falling outside the 90% prediction interval. The numerical predictive check likewise showed 
good predictive performance, with 51.7% (95% CI 44.9, 54.9%) of observed data points 
below the 0% prediction interval (PI), 2.5% (95% CI 1.3, 3.8%) below the 95% PI and 2.4% 
(95% CI 1.4, 3.7%) above the 95% PI.
Simulations of alternative regimens
With both age and weight as predictors of CL/F, simulations were performed to determine 
the proportion of treatments in the following three subgroups of (hypothetical) patients that 
are predicted to have various day 7, as well as maximum, capillary plasma concentrations 
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with alternative dosage regimens: A) 6 month–1 year (weight <10.5 kg), B) 1–2 years 
(weight < 10.5 kg), and C) 1–2 years (weight ≥ 10.5 kg) (Figure 5). PK data for one 
thousand children in each age-weight subgroup, on three occasions each, were simulated. 
The ages were chosen randomly from a uniform distribution. The body weights were 
simulated as a function of those ages, based on the following model of weight that was 
determined from the original data set:
(Equation 2)
in which η1,i represents random variability between patients, and has a variance estimate of 
0.023; η2,i represents random variability within patients, and has a variance estimate of 
0.00173. We chose to use this model to obtain hypothetical weights, rather than derive from 
a published formula or chart, because of the unique population that is represented by the 
patients in this trial.
The currently recommended regimens served as references to the tested alternatives: 1.5 
times the current regimen and 2 times the current regimen. The percentages of simulated 
treatments with a predicted day 7 target of 57 ng/mL are shown in Table 2 and denoted in 
Figure 5. This putative target was chosen because it is the value of capillary plasma 
concentration that corresponds to 30 ng/mL of venous plasma concentration (17), a level 
previously associated with a reduced rate of recrudescent malaria. (18)
With the current regimen, fewer than 40% of children in group A, 20% in group B, and 30% 
in group C are predicted to have a capillary plasma concentration on day 7 of at least 57 
ng/mL. The simulations indicate that, in order for 50% of children to achieve a day 7 
concentration of 57 ng/mL, a dose of at least 1.5 times the reference is needed in groups A 
and C, but at least 2 times the reference dose is needed for group B (1–2 year old children 
with weight < 10.5 kg). Given concerns regarding cardiotoxicity of PQ, particularly QT 
prolongation, (19, 20) we also report the distribution of maximum capillary plasma 
concentrations (Cmax) with each of the regimens simulated, and denote the 75 percentile, 95 
percentile and highest value in each group (Figure 5). The highest Cmax values predicted 
(with the highest doses tested) were approximately 3500 ng/mL, 3600 ng/mL and 3000 
ng/mL, for groups A, B and C, respectively.
Discussion
This study is the largest and amongst the first to report the PK of PQ in children less than 2 
years of age. Although a number of studies have been conducted in adults (4, 6, 21) and 
older children (3, 6, 7, 8, 14) with malaria, it is difficult to compare results of the present 
study to these prior studies because of important differences in trial design. One similarly 
designed study of 2–10 year olds in Burkina Faso, by some of the same investigators as in 
this study, (3) was the first to report the PK of DP in children living in sub-Saharan Africa. 
Both studies used the same drug product, dosing regimen, biologic fluid assayed (capillary 
plasma), assay and importantly, long duration of sample collection, and were able to get a 
stable fit of a three-compartment open model to the PK data. The long estimated terminal 
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t1/2 of approximately 1 month in our study compares to the estimate of 23 days in the 2–10 
year olds and is due primarily to the large peripheral volumes of distribution, approximately 
722 L for one peripheral compartment, and 3990 L for the second peripheral compartment, 
in the typical one year old (approximate weight 8.4 kg).
Other PK studies of PQ reported more than one peak and Roshammar and colleague equated 
it to absorption pattern (5, 22). These investigators did not use the same product as in this 
study, suggesting that the phenomenon has more to do with the drug than the formulation. 
Another possible explanation for a second peak in a portion of patient-treatments is that it 
represents a shift in drug distribution, because when it occurs, it generally appears a week or 
more after dosing.
The most notable finding in our trial of young children is that age as well as body weight is a 
predictor of CL/F, with CL/F increasing as age increases. While allometric scaling takes into 
account differences in body size, it does not account for maturation of enzymes responsible 
for drug metabolism (10). Preliminary studies suggest that PQ is primarily metabolized by 
cytochrome p450 3A4 (CYP3A4), (23) which has the greatest change between 0 and 2 years 
of age. (24, 25) In this current trial, 25% of study participants were mildly underweight and 
13% were moderate-severely underweight. (26) Focusing strictly on average weights, the 
mean weight of a 12-month old Ugandan in our study was 8.0 kg, compared to 9.3 kg from 
the 2009 international WHO chart. (27) Our data suggest that the enzymes responsible for 
PQ metabolism mature chronologically despite weight being less than “normal.” The ability 
to identify an effect of age on CL/F, independent of weight, may have been enhanced in this 
study due to the fact that these two covariates were not strongly correlated (r2 of 0.21) in this 
trial.
As this study was not designed to specifically discern covariate effects on CL versus F (both 
of which directly influence average plasma concentration), we are unable to determine 
through modelling whether the effects of age are predominantly on CL, F or both. Further 
complicating the picture is that CYP3A4 in the gut wall decreases F (and thereby increase 
CL/F), and gut CYP3A4 is also subject to developmental changes. (28) ARVs were not 
identified as interacting with PQ, though the ARV in this study most likely to affect 
CYP3A4, nevirapine, is only a mild-modest inducer. (29) Additionally, there is low power to 
detect a drug interaction because only 10 patients were taking an ART concurrently.
It is important that the PK model for PQ not be extrapolated beyond the limits of the 
population we studied. The GOF of an alternative model for the effect of age on CL/F, in 
which weight-adjusted CL/F increases with age in a first-order manner, could not be 
distinguished from the final model (Equation 2) on the basis of OFV; this model suggests 
that the time for half of the full age effect occurs at approximately 6 months, 75% at 12 
months, 87.5% at 18 months and the age effect virtually complete by 2 years of age. This 
result is consistent with the lack of age effect in the aforementioned study in Burkina Faso in 
2–10 year olds. (3)
What is apparent in both the actual and simulated data is that 1–2 year olds who receive 
lower doses because their weight is below 10.5 kg have lower exposure compared to 
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children who are the same age, but weigh more and receive a higher dose. That is, our 
analysis suggests we are presently underdosing 1 to 2 year olds with lower weight (<10.5 
kg) compared to those with weights ≥ 10.5 kg. In fact, based on the target exposure on day 7 
believed to be “protective” against recurrent malaria, we are underdosing all 3 groups of 
children with the currently recommended dosing regimens (those used in this trial). While 
additional comparisons of our levels to venous levels reported in other studies could be 
informative, we have concentrated our assessments on day 7 comparisons, as these 
correlations have been best defined in the literature. It should be noted that in our study day 
7 concentration was only weakly correlated with AUC (r2=0.11). It would not be surprising 
then, if another marker were found to be better correlated with outcome.
The simulations for the reference doses reasonably matched the data (Table 2), though the 
simulations tended to have more individuals reaching 57 ng/mL on day 7 in the 6 to 12 
month age group than is reflected in the actual data. The main reason for this disparity is 
because the population in the simulation was distributed uniformly within each age group, 
whereas the observed patients in group A tended to be comparatively older (mean age 314 
days versus 272 days), though the weights were similar (both about 7.8 kg).
These finding of underdosing in young chidren are consistent with the Burkina Faso study of 
2 to 10 years old, in which exposure to PQ was lower in younger than older children and 
adults even though the mg/kg dose was higher; these findings resulted in recommendations 
for a revised weight-based dosing scheme (3). With standard allometric scaling of WT raised 
to a power of 0.75 multiplied by some constant, it can be predicted by mathematics alone 
that smaller size individuals have a higher weight adjusted CL, and therefore a higher mg/kg 
dose requirement, than larger individuals. Our findings expand this to suggest that age is 
another important variable for PK in the children less than 2 years of age.
Additional support for a pressing need to re-evaluate DP dosing in children is provided by a 
recent report from the Worldwide Antimalarial Resistance Network (WWARN). (30) Their 
pooled analysis of 26 studies found that risk factors predictive of recrudescence included 
mg/kg dose of PQ as well as age being between of 1–5 years. PK was not available in most 
studies and was not included in their analysis. While their age finding may be related to non-
PK factors such as immunity, our study suggests it could also be related to developmental 
influences of drug disposition beyond body size.
In re-evaluating dosing in young children we must bear in mind that increasing the dose, 
especially without spreading dosage administration over more time, may increase the risk of 
toxicity due to higher Cmax values. Concerns have been raised about potential prolongation 
of the QTc interval with PQ, particularly its peak concentrations. (19) More recently, a study 
of PQ in adults in the setting of preventive administration was halted due to QTc 
prolongation, which was subsequently shown to correlate with Cmax levels. (20) Although 
the risk of QTc interval prolongation remains low, any dosage modifications must take this 
risk, and general tolerability, into consideration.
In summary, this population pharmacokinetic study of piperaquine in Ugandan children 6 
month to 2 years of age confirms and extends the finding that children in the youngest age 
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group have lower systemic drug exposure than older children and adults, supporting the 
urgent need for dosing guidelines that consider both weight and age of young children. (3, 
30, 31) Our simulations show that increasing the doses of piperaquine by at least 50% (i.e., 
from 160 mg to 240 mg for children 6 month to 1 year old, and from 240 to 360 mg in 
children 1 to 2 years old) may be required to achieve concentrations capable of “reducing 
risk” of recurrent infection in most patients. Because the dose of low weight (less than 10.5 
kg) 1 to 2 year old children has not, in the past, accounted for an age effect in CL/F (because 
it has been based on weight alone), their doses should be increased even further. Though the 
safety profile of piperaquine is excellent, (31, 32) the impact of higher doses on safety and 
tolerance in these patients must be considered.
Methods
Study area and population
All parents or guardians provided written informed consent, and ethical approval was 
obtained from the Uganda National Council of Science and Technology, the Makerere 
University Research and Ethics Committee, the University of California San Francisco 
Committee on Human Research (#10-01881), and the Centers for Disease Control and 
Prevention Global AIDS Program (#5145.0). Participants in this PK study were part of a 
larger clinical trial in Tororo, Uganda, comparing the efficacy of artemether/ lumefantrine 
(AL), the 1st line treatment for uncomplicated P. falciparum malaria in Uganda, to DP in 
very young children. (31) Daily TS and triple ART with nevirapine, lamivudine and either 
stavudine or zidovudine were given to all HIV-infected participants, and TS alone to 
designated HIV-exposed participants of HIV-infected mothers until completion of breast-
feeding, as per Ugandan Ministry of Health guidelines.
Children were required to be between 6 months and 2 years of age at the start of treatment 
for a given episode of malaria and could be studied on multiple treatment occasions. 
Enrolment in the PK study began on 5th June, 2008, and continued until 24th October 2008.
Treatment Regimen
DP (Duo-Cotecxin®, Holley-Cotec Pharmaceuticals) was administered as three daily doses 
according to total body weight at the time of diagnosis to achieve target total doses of 
approximately 6.4 mg/kg of dihydroartemisinin (DHA) and 51.2 mg/kg of PQ. DP was 
dosed as 20/160 mg DHA/PQ per dose for patients weighing 5.1–10.4 kg, and 30/240 mg 
DHA/PQ per dose for those weighing 10.5–14.5 kg. All doses were administered by nurses 
in the study clinic as crushed tablets dispersed in approximately 5 mL water, followed by 
150 mL reconstituted cow’s milk (Nido®, Nestle Corporation), which contains 
approximately 5 g of fat, to ensure optimal absorption of PQ. (33) Women who were 
breastfeeding were asked to feed after dosing. The full dose was re-administered if vomiting 
occurred within 30 minutes after dosing. No additional antimalarials or known hepatic 
enzyme inhibitors/inducers were administered during the study, with the exception of TS 
and ART in some patients as described above.
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Samples of 125–200 µL whole capillary blood were obtained by finger prick and collected in 
heparinized microtubes on day 0 (pre-first dose), and days 2, 3 (24 hours post-third dose), 7, 
14, 21 and 28. In order to inform absorption kinetics, day 2 samples were obtained either 
immediately prior to the last dose of DP, or at various intervals for up to 6 h after 
administration of the last DP dose. Day 0 and day 28 samples were added in July and 
August 2008, respectively. The microtubes were centrifuged immediately at 2000 × g for 10 
minutes, and plasma transferred to cryovials that were kept in liquid nitrogen. After 
completion of the study, all samples were transferred on dry ice to the Department of 
Clinical Pharmacology, Bangkok, Thailand for drug quantification.
Sample analysis
Analysis for PQ was conducted using high-throughput liquid chromatography coupled to 
tandem mass spectrometry as described previously. (15) Triplicates of quality-control 
samples at each of three PQ concentration levels were used to ensure precision and accuracy 
during quantification. The coefficients of variation during this quantification were 4.81, 
4.15, and 2.27% at 4.5, 20, and 400 ng/mL, respectively. This method provides a limit of 
detection of 0.375 ng/mL, with a lower limit of quantification of 1.50 ng/mL.
Population Pharmacokinetic Data Analysis
Dose amounts used in the analysis were those of the base (the labelled dose of piperaquine 
tetraphosphate salt multiplied by 0.577). PQ capillary plasma concentrations that were 
below the lower limit of assay sensitivity (n=23; 1.8%) were omitted from the PK data set. 
Also omitted were two outlying concentrations that were 2-fold and 10-fold higher than 
concentrations that preceded them, without an intervening dose. The population PK analysis 
was carried out using nonlinear mixed-effects modelling, with NONMEM®, Version 7.3.0 
(Icon Development Solutions, Elliott City, MD) using first-order conditional estimation with 
interaction. (34) Plots were made using the program R, Version 2.12.1 (The R Foundation 
for Statistical Computing); PsN, Version 3.5, (35) was used for bootstrapping to obtain 
standard errors and 95% confidence intervals, and for numerical and visual predictive 
checks.
The general model building approach began with the simplest reasonable structural and 
statistical models, then tested for more complex structural models and alternative statistical 
models, and lastly, tested for the influence of covariates on the PK parameters. Throughout 
the analysis, the residual error was an exponential model (i.e., error was additive to log-
transformed values of observations). GOF plots were used to evaluate interim and final 
models. Formal testing was performed, regardless of preliminary evaluations, for all 
covariates (except sex) on CL/F; body weight on each volume of distribution term; and age, 
weight, breastfeeding and vomiting status on F.
Hypothesis testing during model development was based on the likelihood ratio test, which 
compares the OFV of full versus reduced models with degrees of freedom (d.f.) equal to the 
difference in the number of parameters. The statistical significance of ΔOFV is based on its 
approximate χ2 distribution. Formal covariate testing was done using (in order) singular 
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addition, stepwise addition, singular deletion, and stepwise deletion. A p-value of 0.005 
(ΔOFV −7.88 with 1 d.f.) was considered significant for the final step (stepwise deletion); 
otherwise a p-value of 0.05 (ΔOFV −3.84 with 1 d.f.) was applied. A nonlinear (power) 
model was used for models of continuous covariates, and a multiplicative model for 
categorical covariates.
A visual predictive check of the final model was performed using a sample size of 1000, and 
a numerical predictive check with 1000 simulated data sets, using the actual data set (with 
107 individuals) as the basis for the distribution of covariate values and study design. In 
addition, simulations with 1000 hypothetical individuals based on the final model, and 
including a correlation of age and weight seen in the actual data, were done to evaluate 
dosing based on both age and weight.
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GOF goodness of fit
OFV objective function value
IIV inter-individual variability
IOV inter-occasion variability
CL capillary plasma clearance
F bioavailability




ka first-order rate constant of absorption
CI confidence interval
CYP3A4 cytochrome P450 3A4
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What is the current knowledge on the topic?
Piperaquine pharmacokinetics has been characterized in adults and children over two 
years of age, but not in younger children. With current piperaquine regimens that are 
based on weight alone, children have lower systemic exposure to piperaquine than adults 
and are at greater risk of recrudescence with acute treatment.
What question does this study address?
This study characterizes the population pharmacokinetics, including covariate effects, of 
piperaquine in children less than two years of age.
What this study add to our knowledge
Like older children, those less than two years of age generally have lower systemic 
exposure than older children and adults, especially if they have lower weights. In addition 
to weight, age of young children is an important determinant of piperaquine disposition, 
bioavailability, or both.
How this might change clinical pharmacology and therapeutics
Together with simulations of alternative regimens as well as other investigations, a 
reassessment of piperaquine dosing recommendations in young children is urgently 
needed.
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Piperaquine capillary plasma concentration-time data in 107 children aged 6 months to 2 
years after treatment with 3 daily doses of either 160 mg (children < 10.5 kg) or 240 mg 
(children ≥ 10.5 kg) piperaquine phosphate.
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Relationship of age and body weight with piperaquine capillary plasma CL/F. Triangles 
represent the average weight and CL/F for each age group. With current doses based on 
whether body weight is above or below 10.5 kg (orange vertical line), those at greatest risk 
of low exposure are children between 1–2 years of age with lower weights.
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Goodness of fit plots for the final population PK model of piperaquine in children, showing 
population predictions (A) and individual predictions (B) versus observations, and 
population predictions (C) and time (D) versus conditional weighted residual. All 
conditional weighted residuals are within the range −4 to 4. The thicker grey lines are 
smooths of the data; the narrow black lines are lines of unity (top panels) or weighted 
residuals of 0 (bottom panels).
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Visual posterior predictive checks showing predictions of median (middle line), 90% 
confidence interval (outer bounds), and 50% confidence interval (inner shaded area) of 
capillary plasma concentrations for population PK model of piperaquine versus time since 
first dose of last treatment in children, by dose: 160 mg every day × 3; first 3 days (A), 160 
mg every day × 3; days 4–28 (B), 240 mg every day × 3; first 3 days (C), and 240 mg every 
day × 3; days 4–28 (D).
Sambol et al. Page 18














Predicted percentage of children (y-axes) with a given piperaquine capillary plasma 
concentration (ng/mL; x-axes) on day 7, and with a given maximum concentration (Cmax) in 
each of three groups, children 6 months to 1 year old weighing less than 10.5 kg (A), 
children 1 to 2 years old weighing less than 10.5 kg (B), and childen 1 to 2 years old 
weighing 10.5 kg or more (C). The vertical dashed lines for day 7 indicate the putative target 
of 57 ng/mL. The vertical dashed lines for Cmax indicate (going from left to right) the 75th 
percentile, the 95th percentiles and the largest value predicted in the 1000 children 
simulated.
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Table 1
Parameter estimates for final population pharmacokinetic model of piperaquine in children aged 6 months to 2 
years
Parameter Estimate SE (%)c 95% CId
Structural Parameters
CL/F (L/h)a 6.34 6 5.54 7.04
  Age effect on CLa 0.35 41 0.06 0.67
Q2/F (L/h)a 10.9 6 9.6 12.2
Q3/F (L/h)a 49.4 32 27.5 98.7
Vc/F (L/8.36 kg) 138 29 67 239
V2/F (L/8.36 kg) 4036 8 3459 4649
V3/F (L/8.36 kg) 700 10 561 832
ka (h−1) 0.274 35 0.155 0.536
Secondary Descriptorsb
Vdss/F (L/8.36 kg) 5420 2.2 5190 5660
t1/2 α (h) 1.54 9.3 1.25 1.82
t1/2 β (h) 41.1 2.5 39.1 43.1
t1/2γ (day) 31.2 1.8 30.2 32.3
AUC0–∞ (µg•h/mL) 71.3 1.5 67.2 72.6
Cday7(ng/mL) 42.5 2.4 39.4 45.9
Cmax (ng/mL) 162 0.7 147 178
Interindividual Variability (CV, %)
CL/F 22 62 15 30
Q2/F 14 97 6 27
Q3/F 70 81 30 117
Vc/F 160 52 100 188
V2/F 31 66 20 46
V3/F 24 96 13 46
ka 144 55 91 186
Interoccasion Variability (CV, %)
CL 22 64 15 29
F 21 59 11 31
Residual error (CV, %) 61 17.3 59 63
Abbreviations: CL=clearance; F=relative bioavailability; Q2=intercompartmental clearance for central compartment and first peripheral 
compartment; Q3=intercompartmental clearance for central compartment and second peripheral compartment; Vc=volume of distribution of the 
central compartment; V2=volume of distribution of the first peripheral compartment; V3=volume of distribution of the second peripheral 
compartment; ka=first-order rate constant of absorption; t1/2α=initial half-life of the ln concentration-time slope; t1/2β=middle half-life of the ln 
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concentration-time slope; t1/2γ=terminal half-life of the ln concentration-time slope; Cday7=observed capillary plasma concentration on day 7; 
Cmax=observed peak capillary plasma concentration
Footnotes:
a
– clearance models: A•(WT/8.36)0.75•B in which A is an estimated value (reported in table) and 8.36 is the approximately median weight (kg) for 
a child 12 months old; B is equal to 1 except for CL/F for which it is equal to (AGE/12), with 0.35 being an estimated value;
b




– 95% confidence interval, from percentile bootstrap estimates
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Table 2









6–12 mo 28.9 37.9 67.5 83.4
1–2 year, wt <10.5 kg 22.1 19.0 44.5 66.9
1–2 year, wt ≥10.5 kg 25.0 28.3 58.5 76.9
*
The reference dose is that currently recommended: 160 mg × 3 if weight is < 10.5 kg and 240 mg × 3 if weight is ≥ 10.5 kg.
The absolute dose amounts are represented by the depth of shading, in the order lightest to darkest: 160 mg, 240 mg, 320 mg, 360 mg and 480 mg.
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